tbuckley/cabot-search huggingface dataset:
Roald Bahr #GenerousInjuryPreventionLeader #UncompromisingOnQuality
Authors: Johann Windt
Journal: British Journal of Sports Medicine (2017)

The alarm rings, a much annoying sound. I sleepwalk, zombie like to the shower, where I spend the next 10 min failing to wake up. I grab a banana and a glass of orange juice as I pass through the kitchen, where one or more family members will usually be having a real breakfast. By consensus I have been requested to not speak to anyone at this stage.

Easy! Hole in one. 23 July 2015! 9-iron off the 14th tee at our local golf club in Kragero.

Reasonable fluency in English. No doubt. I learnt it spending a high school year as an American Field Service exchange student in Reisterstown, Maryland.





Halfway through medical school in Oslo, I wanted to pursue a master’s degree in kinesiology at University of California, Los Angeles (and play college volleyball…). …
Abstract P2-02-04: Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population
Authors: LN Gallardo-Alvarado, DF Cantu-De Leon, T Tusie-Luna, I Tusie-Luna, J Diaz-Chavez, EM Herrera, M Chavez-MacGregor, E Bargallo-Rocha, C Villarreal, LA Herrera.Montalvo, YX Segura-Kato
Journal: Cancer Research (2017)

Abstract Background: Breast cancer in Mexican patients presents in average 10 year earlier compared to other populations. Among patients with TP53 mutations, breast cancer is the most common malignancy. In this study we aim to determine the rate of TP53 mutations among young Mexican breast cancer patients. Methods: Breast cancer patients younger that 45 were retrospectively identified, only patients without BRCA1/2 mutations were included. Clinical records and pedigrees were reviewed. Next generation sequencing test for TP53 was performed from blood specimens. All pathogenic mutations were confirmed by Sanger sequencing and verified if were included in the IACR TP53 database. Results: Among the 78 patients younger than 45yo evaluated and tested with next generation sequencing, we identified 5 patients with a TP53 mutation (6.4%). All were younger than 36 corresponding to a rate of 9.4% of mutations in this group of individuals (n = 53). Two, not previously described, frameshift mutations were found (c.291delC and c.273dupG) and three missense mutations (c.844C&amp;gt;T, c.517G&amp;gt;A, c.604C&amp;gt;T). A VUS c.672G&amp;gt;A that causes a silent mutation in a splicing-donor site was identified. All patients with a TP53 mutation had locally advanced disease and tumors were high grade and Her2 positive. Conclusions: Among Mexican women younger than 45yo, the rate of TP53 mutations was higher than in other populations where it's estimated to be 1%. Among patients younger than 36 the proportion was even higher. All patients had a family history suggestive of Li-Fraumeni syndrome. The VUS found in our series needs a deeper analysis (family segregation, structure and function of the resulting protein). Our results support the international recommendation of performing molecular testing for TP53 in breast cancer patients younger than 35 years. Identification of patients with TP53 mutation has important prognostic, therapeutic and quality of life implications for the proband in addition of the risk reduction strategies and intensive surveillance recommended in their families. Citation Format: Gallardo-Alvarado LN, Cantu-De Leon DF, Tusie-Luna T, Tusie-Luna I, Diaz-Chavez J, Herrera EM, Chavez-MacGregor M, Bargallo-Rocha E, Villarreal C, Herrera.Montalvo LA, Segura-Kato YX. Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-02-04.
Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes
Authors: Victoria T Potter, Pramila Krishnamurthy, ZiYi Lim, Victoria J Tindell, Stephen Devereux, Robert E. Marcus, Robin M. Ireland, Judith C. W. Marsh, Antonio Pagliuca, Ghulam J. Mufti
Journal: Blood (2011)
High-Resolution Genomic Profiling of Myelodysplasia (MDS) by Microarray Comparative Genomic Hybridization (CGH).
Authors: Noor Esoof, Aristoteles Giagounidis, Mario Cazzola, Luca Malcovati, Carlo Aul, Andrea Pellagatti, Carrie Fidler, Sally Killick, David Oscier, Jacqueline Boultwood, James S. Wainscoat
Journal: Blood (2006)
Imatinib Mesylate Treatment Increases Lymphoplasmocytoid Cells through SDF-1 and BMP4/7 Production in the Bone Marrow of Patients with Chronic Myelogenous Leukaemia: Relationship with Clinical/Haematological Response.
Authors: Ivana Pierri, Alessandro Poggi, Silvia Catellani, Francesca Olcese, Marco Gobbi, Maria Raffaella Zocchi
Journal: Blood (2009)
Abstract A13: Development of a drug response assessment platform for biopsy-derived tumor models
Authors: David P. Kodack, Matthew Held, Leah Damon, Dana Lee, Melissa Parks, Richard Dicecca, Max Greenberg, Jeffrey A. Engelman, Cyril H. Benes
Journal: Clinical Cancer Research (2016)

Abstract Our labs have previously described a pharmacogenomic approach to identify therapeutic strategies in cancer cells derived directly from the biopsies of patients. These findings were made in pure cancer cell populations derived on the order of months. Our ultimate goal is to utilize one's own cancer cells for a personalized in vitro diagnostic test. Therefore, we aimed to develop a reliable method to analyze a high-throughput pharmacological screen in mixed cell populations with minimal cancer cells since this is the reality of fresh samples within weeks of the biopsy. The necessity for this is two-fold: first, the culture of patient biopsies is more successful on an irradiated fibroblast feeder layer and, second, noncancerous patient cells, including stromal fibroblasts, often survive biopsy culture. We identified a cocktail of two monoclonal antibodies, one against cytokeratin 8 and another against cytokeratin 18, as a consistent identifier of lung cancer cells that could be used in a high-throughput immunofluorescence-based assay. Drug sensitivity experiments with the immunofluorescence-based assay on patient-derived lung cancer cells mixed with feeder or stromal fibroblasts produced dose-response curves consistent with a pure cancer cell viability assay. We plan to utilize this assay to test the accuracy of patient-derived tumor models, obtained within weeks of biopsy, in mimicking patients' responses to targeted therapy. Ultimately, we hope this approach could help determine therapeutic choices for individual patients. Citation Format: David P. Kodack, Matthew Held, Leah Damon, Dana Lee, Melissa Parks, Richard Dicecca, Max Greenberg, Jeffrey A. Engelman, Cyril H. Benes. Development of a drug response assessment platform for biopsy-derived tumor models. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A13.
Microarray and Proteomic Analysis of Myeloproliferative Neoplasms,
Authors: Vladan P Cokic, Pascal Mossuz, Jing Han, Milos Diklic, Mirela Budec, Dijana Sefer, Danijela Lekovic, Darko Antic, Tijana Brekovic, Sonja Mojsilovic, Raj K Puri, Constance Tom Noguchi, Alan N Schechter
Journal: Blood (2011)
Abstract PR03: The pig as a model for colorectal cancer
Authors: Carolin Wander, Tatiana Flisikowska, Krzysztof Flisikowski, Érica Schulze, Hans-Rudolf Fries, Stefan Bauersachs, Alexander Kind, Angelika Schnieke
Journal: Cancer Research (2017)

Abstract Colorectal cancer is the fourth most common cancer worldwide with a mortality of more than 50%. Contrary to the increasing advances in cancer research colorectal cancer deaths are increasing in number. Most animal models also for colorectal cancer are in rodents. However, mice differ significantly in size, lifespan, physiology, anatomy and diet. Furthermore, genetically engineered mouse models for colorectal cancer show polyp development in the small intestine, contrary to the human phenotype that develops polyps in the large intestine. Therefore, a more suitable animal model is necessary. Pigs are increasingly recognized as a valuable model facilitating diagnostic and therapeutic strategies at human scale, longitudinal studies of disease initiation, progression and treatment response in preclinical trials. We generated gene targeted cloned pigs carrying the nonsense mutation, APC1311 that is orthologous to a human mutation associated with a very severe phenotype of colorectal cancer and the inherited condition familial adenomatous polyposis (FAP). In pigs the APC1311 mutation results in multiple adenomatous polyps in the colon and rectum that, so far, have progressed to carcinoma in situ. Histological and molecular analysis show that the porcine model recapitulates all major features of early stage human FAP. Breeding and analysis of the mutant pig herd has revealed segregation of traits that affect polyposis severity in animals carrying the same APC1311 mutation. We are currently investigating the genetic basis for this effect by comparing normal mucosa samples from low and high polyp animals and have discovered some genes that are differentially expressed. A progression study comparing low-grade with high-grade adenomas also identified differentially expressed genes and miRNAs. Further improvements of this model are targeted at generating organ/tissue specific Cre pigs to activate latent mutations such as KRAS and TP53 mutations in the colon. Additionally to encourage cancer progression we are working on the introduction of ubiquitous Cas9 expression in our APC1311 pigs to allow the activation of oncogenic pathways locally in vivo. Our porcine model provides a powerful new resource for preclinical cancer research, including identifying and investigating novel biomarkers for early detection. This abstract is also being presented as Poster A20. Citation Format: Carolin Wander, Tatiana Flisikowska, Krzysztof Flisikowski, Érica Schulze, Hans-Rudolf Fries, Stefan Bauersachs, Alexander Kind, Angelika Schnieke. The pig as a model for colorectal cancer. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr PR03.
Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)
Authors: Issa F. Khouri, Roland Bassett, Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E. Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Alessandra Ferrajoli, Richard Champlin, John McMannis, Marcelo Fernandez-Vina
Journal: Blood (2010)
Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up
Authors: M. Ströhlein, F. Lordick, D. Rüttinger, O. Schemanski, M. Jaeger, H. Lindhofer, M. Hennig, A. Lahr, M. Heiss
Journal: Journal of Clinical Oncology (2009)

3033 Background: Peritoneal carcinomatosis (PC) from gastrointestinal (GI) cancer is associated with a poor outcome. The trifunctional antibody catumaxomab may induce remission by redirecting T-lymphocytes and Fcγ-receptor I/III positive accessory cells to tumor cells. The aim of this study was to investigate the treatment of PC with intraperitoneal catumaxomab. Methods: Patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer were enrolled in a multicenter phase I study and received four sequential intraperitoneal catumaxomab infusions on days 0, 3, 7, and 10 at increasing doses. Results: Twenty-four patients were enrolled. The maximum tolerated dose (MTD) was reached at 10, 20, 50, and 200 μg on days 0, 3, 7, and 10, respectively. The most common drug-related adverse events at the MTD were fever, vomiting, abdominal pain, skin toxicity, and nausea. Eleven of 17 evaluable patients (65%) were progression-free at final examination: one patient had a complete response and three patients had a partial response. EpCAM-positive cells in peritoneal lavage samples decreased in six of 10 evaluable patients. Patient survival was compared in a post hoc matched-pair analysis with PC patients treated with conventional intravenous chemotherapy. Median survival from the time of diagnosis of PC was 502 days in study patients versus 180 days in control patients (log-rank p = .0083). Conclusions: Intraperitoneal treatment with catumaxomab had an acceptable safety profile. Elimination of tumor cells from peritoneal lavage samples, delayed disease progression, and prolonged survival indicate that intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer. [Table: see text]
FMNL-1 (Formin-Like 1) Gene in Chronic Lymphocytic Leukemia (CLL) Is Overexpressed in Young Patients with Adverse Prognostic Factors and Poor Outcome.
Authors: Eva Calpe, Patricia M.B. Favaro, Marta Crespo, Maria Joao Baptista, Ana Muntañola, Eva Giné, Sara Saad, Emili Montserrat, Francesc Bosch
Journal: Blood (2006)
Annals Story Slam - Reframe
Authors: Michael Bohannan-Calloway
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 March 2017Annals On Being a Doctor Story Slam - ReframeFREEMichael Bohannan-Calloway, PhDMichael Bohannan-Calloway, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0028 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Reframe "Reframe," by Michael Bohannan-Calloway (Duration 5:37)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Anjana BhanMax Healthcare26 January 2022 Well done Was very touched and inspired by this video. I have been a patient and am a Doctor too. I can very well relate to this story. Take care. All the Best. Disclosures: Max healthcare Author, Article, and Disclosure InformationAffiliations: Current Author Address: Michael Bohannan-Calloway, PhD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 March 2017Volume 166, Issue 5Page: SS1 ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma
Authors: Bruce D. Cheson, Peter C Trask, John Gribben, Natalie Dimier, Eva Kimby, Pieternella J Lugtenburg, Catherine Thieblemont, Elisabeth Wassner Fritsch, Laurie H Sehn
Journal: Blood (2015)
NK Cytotoxicity Is Decreased During the Early Posttransplant Period Following Pediatric Allogeneic Transplantation From Unrelated Donors Using CD3/CD19-Depleted Graft.
Authors: Antonio Pérez-Martínez, Manuel Ramírez, María Ruiz-Salmerón, Marta Gonzalez-Vicent, S. Grande, Alvaro Lassaletta, Juliáan Sevilla, Jose Francisco Tomas, Luis Madero, Miguel Angel Diaz
Journal: Blood (2009)
Cig-FISH-Analysis of Extramedullary Myeloma Manifestations Shows Similar Incidence of Prognostic Genetic Aberrations Compared to Bone Manifestations or Soft Tissue Involvement
Authors: Lisa Billecke, Eva Maria Murga Penas, Annette May, Monika Engelhardt, Arnon Nagler, Merav Leiba, Nicolaus Kröger, Jozef Zustin, Andreas Marx, Jakob Matschke, Markus Tiemann, Eray Gökkurt, Carsten Bokemeyer, Georgia Schilling
Journal: Blood (2010)
Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer
Authors: N. J. Bundred, G. Landberg, R. E. Coleman, J. Morris, M. C. Winter, I. Holen, A. Cramer, L. Renshaw, S. Grassby, J. M. Dixon
Journal: Journal of Clinical Oncology (2009)

e11625 Background: Aromatase inhibitors (AIs) reduce tumor cell proliferation and improve breast cancer survival. Recent evidence from in vivo models and the ABCSG-12 Trial suggests that bisphosphonates such as zoledronic acid add to the inhibitory effect of AIs but the mechanism is unclear. We assessed the effect of letrozole alone and in combination with zoledronic acid in a 14 day pre-surgical study in women with primary breast cancer. Methods: Postmenopausal women (n=109) aged 50–75 years with untreated estrogen receptor positive invasive breast cancer (no prior hormonal therapy) gave written informed consent to the study and were randomized to letrozole (2.5mg) or placebo tablets (2:1). Letrozole treated patients were randomized further to zoledronic acid 4mg intravenously or no treatment 2–4 days prior to surgery. Epithelial proliferation and apoptosis was measured pre and post treatment by immunohistochemistry for Ki67 and activated caspase 3 respectively counting at least 1,000 cells. Smooth Muscle Actin immunohistochemistry was also assessed pre and post treatment to determine fibroblast activation. Results: The study is powered to detect a 10% difference in epithelial proliferation with the combination arm (80% chance) compared to the letrozole alone arm. Conclusions: This preoperative biological study should provide important insight into the cellular mechanism or action of zoledronic acid in addition to AIs on primary breast cancer. [Table: see text]
Clinical Significance of Myelofibrotic (MF) Changes in Myelodysplastic Syndromes (MDS): A Prospective Evaluation Including Mutational Analysis By Next-Generation Sequencing (NGS)
Authors: Fernando Ramos, Cristina Robledo, Francisco Miguel Izquierdo-García, Dimas Suárez-Vilela, Rocío Benito, Marta Fuertes, Andrés Insunza, Eva Barragan, Mónica del Rey, José María García-Ruiz de Morales, Mar Tormo, Eduardo Salido, Lurdes Zamora, Carmen Pedro, Javier Sánchez-del-Real, María Díez-Campelo, Consuelo del Cañizo, Guillermo F. Sanz, Jesus Maria Hernández-Rivas
Journal: Blood (2014)
Abstract B45: Silencing ß3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer
Authors: Jenny G. Parvani, Maneesh D. Gujrati, Margaret A. Mack, William P. Schiemann, Zheng-Rong Lu
Journal: Cancer Research (2017)

Abstract Metastatic breast cancer is the second leading cause of cancer-related deaths among women. Triple-negative breast cancer (TNBC) is a highly aggressive subcategory of breast cancer and currently lacks well-defined molecular targets for effective targeted therapies. Disease relapse, metastasis, and drug resistance render standard chemotherapy ineffective in the treatment of TNBC. Because previous studies coupled β3 integrin (ITGB3) to epithelial-mesenchymal transition (EMT) and metastasis, we exploited β3 integrin as a therapeutic target to treat TNBC by delivering β3 integrin siRNA via lipid ECO-based nanoparticles (ECO/siβ3). Treatment of TNBC cells with ECO/siβ3 was sufficient to effectively silence β3 integrin expression, attenuate TGFβ;-mediated EMT and invasion, restore TGFβ-mediated cytostasis, and inhibit three-dimensional organoid growth. Modification of ECO/siβ3 nanoparticles with an RGD peptide via a PEG spacer enhanced siRNA uptake by post-EMT cells. Intravenous injections of RGD-targeted ECO/siβ3 nanoparticles in vivo alleviated primary tumor burden and, more importantly, significantly inhibited metastasis. In the span of 16 weeks of the experiments and observations, including primary tumor resection at week 9 and release from the treatment for 4 weeks, the mice bearing orthotopic, TGFβ-prestimulated MDA-MB-231 tumors that were treated with RGD-targeted ECO/siβ3 nanoparticles were free of metastases and relapse, in comparison with untreated mice. Collectively, these results highlight ECO/siβ3 nanoparticles as a promising therapeutic regimen to combat TNBC. Citation Format: Jenny G. Parvani, Maneesh D. Gujrati, Margaret A. Mack, William P. Schiemann, Zheng-Rong Lu. Silencing ß3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B45.
Exosomes Mediate Communication Between the Microenvironment and Leukemic Cells in Acute Myeloid Leukemia
Authors: Peter P. Ruvolo, Rodrigo Jacamo, Vivian R Ruvolo, Jared K Burks, V Lokesh Battula, Teresa McQueen, Marina Konopleva, Steven M. Kornblau, Ramiro Garzon, Carlo M. Croce, Michael Andreeff
Journal: Blood (2012)
Intensive care medicine research agenda on cardiac arrest
Authors: Jerry P. Nolan, Robert A. Berg, Stephen Bernard, Bentley J. Bobrow, Clifton W. Callaway, Tobias Cronberg, Rudolph W. Koster, Peter J. Kudenchuk, Graham Nichol, Gavin D. Perkins, Tom D. Rea, Claudio Sandroni, Jasmeet Soar, Kjetil Sunde, Alain Cariou
Journal: Intensive Care Medicine (2017)